Yearly Archives: 2024

• 

Belzutifan and shows better quality of life compared to everolimus

By Sharon Deveson Kell|2024-02-02T09:29:08+00:002 Feb 2024|Drug treatments|

People with kidney cancer have been shown to have changes [...]

Read More

Comments Off on Belzutifan and shows better quality of life compared to everolimus

• 

Lenvatinib plus pembrolizumab for advanced kidney cancer

By Sharon Deveson Kell|2024-01-18T08:54:41+00:0018 Jan 2024|Drug treatments|

The final survival information from the phase 3 CLEAR study [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab for advanced kidney cancer

• 

Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer

By Sharon Deveson Kell|2024-01-16T15:43:53+00:0016 Jan 2024|Drug treatments|

In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]

Read More

Comments Off on Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer

• 

METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer

By Sharon Deveson Kell|2024-01-09T16:10:37+00:009 Jan 2024|Drug treatments|

Cabozantinib is a tyrosine kinase inhibitor that is used [...]

Read More

Comments Off on METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer

• 

‘No stupid questions’ for newly diagnosed kidney cancer patients

By Sharon Deveson Kell|2024-01-09T09:46:55+00:009 Jan 2024|Patient advocacy|

In this recent video interview, Dr Rachel Giles, chief executive [...]

Read More

Comments Off on ‘No stupid questions’ for newly diagnosed kidney cancer patients